Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of LY06006 in Postmenopausal Osteoporosis
NCT05060406Phase 3Unknown
- Sponsor
- Luye Pharma Group
- Start
- Jun 2019
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of CMAB807 in postmenopausal osteoporosis, sponsored by Luye Pharma Group. Status: unknown.
02
Drugs
CMAB807
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT05060406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060406.